AU709108B2 - Therapeutic agent for acute lung injury resulting from indirect causes comprising anti-IL-8 antibody as active ingredient - Google Patents

Therapeutic agent for acute lung injury resulting from indirect causes comprising anti-IL-8 antibody as active ingredient Download PDF

Info

Publication number
AU709108B2
AU709108B2 AU32753/97A AU3275397A AU709108B2 AU 709108 B2 AU709108 B2 AU 709108B2 AU 32753/97 A AU32753/97 A AU 32753/97A AU 3275397 A AU3275397 A AU 3275397A AU 709108 B2 AU709108 B2 AU 709108B2
Authority
AU
Australia
Prior art keywords
antibody
lung injury
acute lung
indirect
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU32753/97A
Other languages
English (en)
Other versions
AU3275397A (en
Inventor
Kouji Matsushima
Kenji Yokoi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU3275397A publication Critical patent/AU3275397A/en
Application granted granted Critical
Publication of AU709108B2 publication Critical patent/AU709108B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU32753/97A 1996-06-26 1997-06-26 Therapeutic agent for acute lung injury resulting from indirect causes comprising anti-IL-8 antibody as active ingredient Ceased AU709108B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP8-200918 1996-06-26
JP20091896 1996-06-26
JP8-315378 1996-10-22
JP31537896 1996-10-22
PCT/JP1997/002221 WO1997049426A1 (fr) 1996-06-26 1997-06-26 Medicaments destines aux lesions pulmonaires aigues dues a des causes indirectes, contenant un anticorps anti-il-8 comme principe actif

Publications (2)

Publication Number Publication Date
AU3275397A AU3275397A (en) 1998-01-14
AU709108B2 true AU709108B2 (en) 1999-08-19

Family

ID=26512471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32753/97A Ceased AU709108B2 (en) 1996-06-26 1997-06-26 Therapeutic agent for acute lung injury resulting from indirect causes comprising anti-IL-8 antibody as active ingredient

Country Status (6)

Country Link
US (1) US20020141988A1 (US06373033-20020416-M00071.png)
EP (1) EP0955060A1 (US06373033-20020416-M00071.png)
KR (1) KR20000022238A (US06373033-20020416-M00071.png)
AU (1) AU709108B2 (US06373033-20020416-M00071.png)
CA (1) CA2254782A1 (US06373033-20020416-M00071.png)
WO (1) WO1997049426A1 (US06373033-20020416-M00071.png)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE527278T1 (de) 2002-12-16 2011-10-15 Genmab As Humane monoklonale antikörper gegen interleukin 8 (il-8)
SG11202005323SA (en) 2018-01-12 2020-07-29 Bristol Myers Squibb Co Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002576A1 (fr) * 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
WO1996022785A1 (en) * 1995-01-23 1996-08-01 The Regents Of The University Of California Methods for the treatment of acid aspiration-induced acute lung injury

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE913192A1 (en) * 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
EP0749488A1 (en) * 1994-03-03 1996-12-27 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002576A1 (fr) * 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
WO1996022785A1 (en) * 1995-01-23 1996-08-01 The Regents Of The University Of California Methods for the treatment of acid aspiration-induced acute lung injury

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. CLIN. INVEST., 1995, VOL. 155, PP. 107-116 *

Also Published As

Publication number Publication date
WO1997049426A1 (fr) 1997-12-31
CA2254782A1 (en) 1997-12-31
US20020141988A1 (en) 2002-10-03
AU3275397A (en) 1998-01-14
EP0955060A1 (en) 1999-11-10
EP0955060A4 (US06373033-20020416-M00071.png) 1999-11-10
KR20000022238A (ko) 2000-04-25

Similar Documents

Publication Publication Date Title
CA2341239C (en) A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient
US7771723B2 (en) Remedies for myeloma to be used together with nitrogen mustard antitumor agents
KR101218532B1 (ko) 혈관염 치료제
US8945558B2 (en) Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
US8562990B2 (en) Method of treating psoriatic arthritis with an IL-6 receptor antibody
US8617550B2 (en) Treatment of vasculitis with IL-6 antagonist
US20060165696A1 (en) Remedy for spinal injury containing interleukin-6 antagonist
WO2002036165A1 (fr) Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
US20010006637A1 (en) Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient
AU709108B2 (en) Therapeutic agent for acute lung injury resulting from indirect causes comprising anti-IL-8 antibody as active ingredient
JP4854102B2 (ja) 抗ｉｌ−８抗体を有効成分として含有する間接的原因に起因する急性肺損傷治療剤
US20020006405A1 (en) Sepsis remedy comprising anti-il-8 antibody as active ingredient
WO1997040215A1 (fr) Medicament contre l'infarctus du myocarde contenant comme principe actif un anticorps anti-il-8
JP4404968B2 (ja) Ｉｌ−８結合阻害物質を有効成分として含有する脳卒中及び脳浮腫の予防または治療剤
KR20230140362A (ko) 항-Fetuin-B 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물
KR20200074160A (ko) 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
JPH1045622A (ja) 抗ｉｌ−８抗体を有効成分として含有する慢性関節リウマチ治療剤
JPH1053536A (ja) 抗ｉｌ−８抗体を有効成分として含有する心筋梗塞治療剤
JPH10182488A (ja) 抗ｉｌ−８抗体を有効成分として含有する敗血症治療剤